Hjem › Blærecancer › Florida › Gainesville
Blærecancer kliniske forsøg i Gainesville, FL
4 studier for Blærecancer søger deltagere på steder i og omkring Gainesville (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RekruttererFase 3
- UF Health Cancer Institute - Gainesville, Gainesville
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
RekruttererFase 2
- UF Health Cancer Institute - Gainesville, Gainesville
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RekruttererFase 2
- University of Florida, Gainesville
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RekruttererFase 2
- University of Florida, Gainesville
Blærecancer forsøg i andre byer
- New York City, NY35 studier
- Nashville, TN31 studier
- Houston, TX31 studier
- Dallas, TX27 studier
- Boston, MA26 studier
- Washington, DC26 studier
- Los Angeles, CA24 studier
- Baltimore, MD24 studier
- St. Louis, MO22 studier
- Philadelphia, PA21 studier
- Seattle, WA21 studier
- Edison, NJ21 studier
Andre studier i Gainesville
- Hjertesvigt13 studier
- Brystkræft12 studier
- Type 1-diabetes12 studier
- Parkinsons sygdom12 studier
- Ikke-småcellet lungecancer10 studier
- Colorektal kræft9 studier
- Lungecancer9 studier
- Kræft (alle typer)9 studier
- Kardiovaskulær sygdom9 studier
- Prostatakræft8 studier
- Let kognitiv svækkelse8 studier
- Akut myeloid leukæmi8 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.